Search Results
Your search for ,aLl matches 18305 pages
Showing 4901 - 4950Ixazomib/Rituximab/Dexamethasone for Relapsed or Refractory Waldenström’s Macroglobulinemia
In a phase I/II trial (HOVON124/ECWM-R2) reported in the Journal of Clinical Oncology, Kersten et al found that the combination of oral ixazomib with subcutaneous rituximab and dexamethasone showed efficacy in patients with relapsed or refractory Waldenström’s macroglobulinemia, with a manageable...
Antihypertensive Medications May Improve Survival Among Patients With Stage I to III Colorectal Cancer
Commonly used blood pressure drugs may improve survival for patients with colorectal cancer, a recent study published by Balkrishnan et al in Cancer Medicine suggests. After reviewing outcomes of almost 14,000 patients with colorectal cancer, researchers determined that angiotensin-converting...
Report Aims to Assess Contemporary Burden of Brain Tumors in the United States
A new study found that incidence rates for malignant brain and other central nervous system (CNS) tumors declined by 0.8% annually during 2008 through 2017 in the United States for all ages combined. The decline was driven by trends in adults, whereas rates have slightly increased by 0.5% to 0.7%...
Does Radiotherapy Reduce the Long-Term Risk of Ipsilateral Breast Recurrence in Women With DCIS Who Underwent Lumpectomy?
In an analysis of long-term outcomes from the phase III NRG/RTOG 9804 trial reported in the Journal of Clinical Oncology, Beryl McCormick, MD, and colleagues found that whole-breast irradiation vs observation was associated with reduced risk of all and invasive ipsilateral breast recurrence at 15...
Study Finds Evidence-Based Interventions Added to Screening Did Not Improve Cancer Pain
When added to regular screening and guidelines, evidence-based interventions implemented at the patient, health professional, and service levels did not significantly improve cancer pain, according to research led by Melanie Lovell, MBBS, PhD, Medical Head of Palliative Care at HammondCare and...
ASCO and MASCC/ISOO Publish Joint Guideline on Prevention, Treatment of Salivary Gland Hypofunction and Xerostomia
A new joint ASCO guideline offers clinicians updated evidence-based recommendations for the prevention and treatment of salivary gland hypofunction and xerostomia caused by nonsurgical cancer therapies.1 The guidance was developed together by ASCO and the Multinational Association of Supportive...
ASCO Joins Statement Supporting Mandatory Health Employer COVID-19 Vaccination
With COVID-19 case counts rising amid the spread of the Delta variant, ASCO has joined more than 50 health-care professional societies and organizations that represent millions of workers throughout health and long-term care in calling for all health-care employers to require their employees to be...
Neuroendocrine Tumor Specialist Pamela Kunz, MD, Looks to Promote Equity in the Workforce
In this installment of the Living a Full Life series, guest editor Jame Abraham, MD, spoke with Pamela Kunz, MD, Director, Center for Gastrointestinal Cancers at Smilow Cancer Hospital and Yale Cancer Center. Dr. Kunz is an international leader in the clinical care of patients with neuroendocrine...
High Prevalence of Previously Undiagnosed Emphysema Among Individuals Undergoing Low-Dose CT Screening for Lung Cancer
In a prospective cohort study reported in Clinical Imaging, David Steiger, MD, of the Division of Pulmonary, Critical Care and Sleep Medicine, Icahn School of Medicine at Mount Sinai, in New York, and colleagues in the International Early Lung Cancer Action Program (I-ELCAP) identified emphysema in ...
New Guideline Provides Clarity on Timing, Treatment of Axilla in Early-Stage Breast Cancer
ASCO and Ontario Health (Cancer Care Ontario) have collaborated to release a new clinical practice guideline on the management of the axilla in early-stage breast cancer.1 “A lot has changed in the past several years with regard to de-escalating the amount of treatment women are offered in the...
Isatuximab-irfc in Relapsed or Refractory Multiple Myeloma
On March 31, 2021, the anti-CD38 monoclonal antibody isatuximab-irfc was approved for use in combination with carfilzomib and dexamethasone for the treatment of adults with relapsed or refractory multiple myeloma who have received one to three prior lines of therapy.1 Supporting Efficacy Data...
Historic, Present, and Future Perspectives on Breast Cancer in Egypt
Breast cancer is the most frequently diagnosed cancer among women around the world, making it a significant public health problem.1 The disease affects both men and women, although it is rare in men, accounting for just 1% of all breast cancer diagnoses in the United States and less than 0.1% of...
Low-Dose CT Screening for Lung Cancer and the Incidental Findings That May Improve Future Health
Every interaction with patients is an opportunity to change the course of their lives. In the context of screening for disease, every encounter is an opportunity to detect the precursors or early changes that signal early pathophysiology. Smoking status and age are the factors that currently...
Axicabtagene Ciloleucel Improves Multiple Clinical Endpoints in Relapsed Follicular Lymphoma
For the treatment of relapsed or refractory follicular lymphoma, updated data from the ZUMA-5 trial, as compared with the findings of the external control cohort of SCHOLAR-5, showed substantial improvement in all key clinical endpoints with axicabtagene ciloleucel, ZUMA-5 investigators reported in ...
FDA Pipeline: Reviews for Agents in Acute Graft-vs-Host Disease, Nasopharyngeal and Ovarian Cancers
Recently, the U.S. Food and Drug Administration (FDA) granted Priority Review to an agent for the prevention of acute graft-vs-host disease; Breakthrough Therapy designation to an anti–PD-1 monoclonal antibody for the treatment of metastatic nasopharyngeal carcinoma; and Fast Track designation to a ...
Study Examines Link Between Obesity in Long-Term Cancer Survivors and Increased Health-Care Utilization and Spending
A new study from the American Cancer Society published by Xuesong Han, PhD, and colleagues in the journal Cancer has found a link between obesity and the substantial economic burden of nearly $20 billion in 2016 among long-term cancer survivors in the United States, with one-third attributable to...
Patients With Melanoma Previously Treated With PD-1 or MAPK Inhibitors May Be Less Likely to Respond to ACT-TIL Therapy
Patients with metastatic melanoma who were previously treated with PD-1 or MAPK inhibition are significantly less likely to develop durable objective responses to adoptive cell transfer of tumor-infiltrating lymphocytes (ACT-TIL) than patients naive to these treatments, according to a study...
FDA Grants Approval to the Pfizer-BioNTech COVID-19 Vaccine
On August 23, the U.S. Food and Drug Administration (FDA) approved the first COVID-19 vaccine. The vaccine has been known as the Pfizer-BioNTech COVID-19 vaccine, and will now be marketed as Comirnaty, for the prevention of COVID-19 disease in individuals aged 16 years and older. The vaccine also...
Caution With Robotically Assisted Surgical Devices for Mastectomy: FDA Safety Communication
The U.S. Food and Drug Administration (FDA) is reminding patients and health-care providers that the safety and effectiveness of robotically assisted surgical devices for use in mastectomy procedures or in the prevention or treatment of breast cancer have not been established. In addition, the FDA...
Combination of Lenvatinib and Etoposide/Ifosfamide for Relapsed or Refractory Osteosarcoma
In the phase I/II ITCC-050 trial reported in The Lancet Oncology, Gaspar et al found that the combination of lenvatinib with etoposide/ifosfamide showed antitumor activity, including good progression-free survival outcomes, in patients with relapsed or refractory osteosarcoma. Study Details...
Physical Activity and Cognitive Function Before, During, and After Chemotherapy for Breast Cancer
In a study reported in the Journal of Clinical Oncology, Elizabeth A. Salerno, PhD, MPH, and colleagues found that higher levels of physical activity before and during chemotherapy in women with early-stage breast cancer was associated with better cognitive function outcomes at up to 6 months...
Outcomes Notably Improving for Adult ALL
Outcomes in adults with acute lymphoblastic leukemia (ALL) are almost rivaling those in pediatric ALL, thanks to the benefits achieved by incorporating blinatumomab and inotuzumab into chemotherapy regimens. New ways of administering the chemotherapy component are also increasing tolerability and...
Early-Phase Study Rediscovers Potential Alternative to Methadone for Cancer Pain
Levorphanol was associated with improved pain and symptom control in patients with advanced cancer, according to data from an early phase I trial, reported by Akhila Reddy, MD, at the 2021 Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology (MASCC/ISOO)...
Study Identifies Possible New Genetic Biomarkers of Pediatric Leukemia
In a study published by Magnum et al in JAMA Oncology, researchers reported on how two separate DNA changes appear to predict aggressive childhood leukemias when they occur in combination. The team evaluated tumor characteristics of more than 1,300 pediatric patients with B-cell acute lymphoblastic ...
Cetuximab Plus Avelumab as Rechallenge Therapy for RAS Wild-Type Metastatic Colorectal Cancer
In an Italian phase II trial reported in JAMA Oncology, Martinelli et al found that cetuximab rechallenge plus avelumab showed activity and was well tolerated in patients with RAS wild-type metastatic colorectal cancer who had responded to first-line chemotherapy plus an anti-EGFR agent and then...
Avelumab Under Study as Adjunct to Neoadjuvant Therapy for Rectal Cancer
In the treatment of newly diagnosed locally advanced rectal cancer, two phase II studies evaluating the addition of the PD-L1 inhibitor avelumab to chemoradiotherapy showed promising rates of pathologic complete response, major pathologic response, and tumor downstaging. The study investigators...
Prediction Models May Reduce False-Positives in Women With Dense Breasts Undergoing MRI Screening
Prediction models based on clinical characteristics and imaging findings may help reduce the false-positive rate in women with dense breasts who undergo supplemental breast cancer screening with magnetic resonance imaging (MRI), according to a study published by den Dekker et al in the journal...
Donor-Derived CD7 CAR T Cells May Lead to Remissions in Patients With Relapsed or Refractory T-ALL
In a Chinese single-institution phase I study reported in the Journal of Clinical Oncology, Pan et al found that donor-derived CD7 chimeric antigen receptor (CAR) T-cell therapy produced a high complete remission rate in patients with relapsed or refractory T-cell acute lymphoblastic leukemia...
Retrospective Study Compares Characteristics of Early-Onset vs Average-Onset Colorectal Cancer
A large retrospective study has found that early-onset colorectal cancers are clinically and genomically indistinguishable from average-onset colorectal cancers. In addition, the study found that more aggressive treatment based solely on the patient’s age at diagnosis is neither necessary nor...
Study Identifies Potential Mechanisms of Resistance to Sacituzumab Govitecan-hziy in Patients With Triple-Negative Breast Cancer
Researchers have determined how a highly aggressive type of breast cancer may evade treatment with the compound sacituzumab govitecan-hziy, according to findings published by Coates et al in Cancer Discovery. Their results could help improve therapy and ultimately prolong survival for patients with ...
Does Sparing the Hippocampus During Prophylactic Cranial Irradiation for SCLC Help to Preserve Cognitive Function?
In the Spanish phase III PREMER trial reported in the Journal of Clinical Oncology, Rodríguez de Dios et al found that hippocampal avoidance during prophylactic cranial irradiation (PCI) for small cell lung cancer (SCLC) was associated with better preservation of cognitive function vs PCI alone and ...
Simulation Model–Based Clinical Decision Tool for Predicting Benefit of Adjuvant Chemoendocrine vs Endocrine Therapy in HR-Positive, HER2-Negative Breast Cancer
As reported in the Journal of Clinical Oncology, Jayasekera et al have developed a clinical decision tool called BTxChoice that can be used with or without the 21-gene recurrence score to estimate the potential benefit of adjuvant chemoendocrine vs endocrine therapy in women with node-negative,...
Addition of Entinostat to Exemestane in Aromatase Inhibitor–Resistant, HR-Positive, HER2-Negative Advanced Breast Cancer
As reported in the Journal of Clinical Oncology by Roisin M. Connolly, MB, BCh, MD, and colleagues, the phase III ECOG-ACRIN Cancer Research Group E2112 trial showed no significant improvement in progression-free or overall survival with the addition of the histone deacetylase inhibitor entinostat...
Analyses Examine Relationship Between Treatment With PARP Inhibitors and Risk of Secondary Malignancies
Although poly (ADP-ribose) polymerase (PARP) inhibitors interfere with DNA repair processes, leading to warnings in terms of risk for developing second primary malignancies, findings from a systematic review and safety meta-analysis of placebo-controlled randomized studies are reassuring for...
Teclistamab Shows Efficacy, Produces Durable Responses in Relapsed or Refractory Multiple Myeloma
In a phase I trial (MajesTEC-1) reported in The Lancet, Saad Z. Usmani, MD, FACP, and colleagues found that the B-cell maturation antigen (BCMA)-CD3 bispecific antibody teclistamab produced a high rate of durable responses at the recommended phase II dose in patients with relapsed or refractory...
Meta-analysis of Outcomes With the Addition of Adjuvant Trastuzumab to Chemotherapy for HER2-Positive Breast Cancer
In a study conducted by the Early Breast Cancer Trialists’ Collaborative Group and reported in The Lancet Oncology by Bradley et al, an individual patient data meta-analysis of randomized trials has shown that the addition of adjuvant trastuzumab to chemotherapy reduces the risk of disease...
FDA Approves Belzutifan for Cancers Associated With von Hippel-Lindau Disease
On August 13, the U.S. Food and Drug Administration (FDA) approved belzutifan (Welireg), a hypoxia-inducible factor inhibitor, for adult patients with von Hippel-Lindau (VHL) disease who require therapy for associated renal cell carcinoma (RCC), central nervous system (CNS) hemangioblastomas, or...
Financial Toxicity Associated With Atherosclerotic Cardiovascular Disease and Cancer
In a study of National Health Interview Survey (NHIS) data reported in JACC: CardioOncology, Valero-Elizondo et al found that U.S. adult patients with atherosclerotic cardiovascular disease (ASCVD) were at greater risk of financial toxicity than those with cancer alone, with risk being the greatest ...
Causes of Death Among Men Diagnosed With Metastatic Prostate Cancer
In a retrospective cohort study using Surveillance, Epidemiology, and End Results (SEER) data reported in JAMA Network Open, Elmehrath et al found that a substantial proportion of men diagnosed with metastatic prostate cancer between 2000 and 2016 in the United States died from causes unrelated to...
Vincristine/Irinotecan With or Without Temozolomide for Relapsed or Refractory Rhabdomyosarcoma
In a European phase II trial (VIT-0910) reported in the Journal of Clinical Oncology, Defachelles et al found that the combination of vincristine/irinotecan with vs without temozolomide produced better outcomes—albeit with increased toxicity—in children and adults with relapsed or refractory...
FDA Pipeline: Reviews for Agents in Lung Cancer, Thyroid Cancer, Kidney Cancer, and More
Recently, the U.S. Food and Drug Administration (FDA) accepted applications for agents aiming to treat non–small cell lung cancer (NSCLC), differentiated thyroid cancer, renal cell carcinoma (RCC), hypersensitive acute lymphoblastic leukemia (ALL), mucosal melanoma, and endometrial carcinoma....
Do Muscle-Strengthening Activities Plus Aerobic Activities Reduce Cancer Mortality?
Regular muscle-strengthening exercises associated with aerobic activities can reduce cancer mortality, according to a systematic review of epidemiologic studies published by Nascimento et al in the International Journal of Behavioral Nutrition and Physical Activity. Workouts with activities like...
Effect of Regionalization of Gastric Cancer Care in an Integrated Health-Care System
In a retrospective cohort study reported in the Journal of Clinical Oncology, Teh et al found that regionalization of gastric cancer care in a U.S. integrated health-care system resulted in the increased use of laparoscopic gastrectomy and D2 lymphadenectomy, as well as improved overall survival...
Evaluation of Baseline Cancer Mortality Risk in Medicaid Expansion and Nonexpansion States
In a study of National Cancer Database data reported in a research letter in JAMA Oncology, Salazar et al found little difference in baseline cancer mortality rates between U.S. states that expanded Medicaid enrollment and nonexpansion states prior to expansion in 2009 and immediately following...
Risk of Early Cardiac Toxicity With Posttransplantation Cyclophosphamide After HSCT
In a French single-center retrospective cohort study reported in JACC: CardioOncology, Duléry et al found that posttransplantation cyclophosphamide was associated with a significantly increased risk of early cardiac events among patients receiving allogeneic hematopoietic stem cell transplantation...
Outcomes and Behaviors Among Women Receiving or Declining Their Breast Cancer Polygenic Risk Score
A recent study examined patient-reported outcomes and risk-management behaviors of women choosing to receive or decline their breast cancer polygenic risk scores (PRS). The findings were published by Tatiane Yanes, PhD, and colleagues in Genetics in Medicine. The research aimed to look at how the...
Enrollment of AYA Patients Into NCI-Sponsored Clinical Trials: 25-Year Analysis
Adolescent and young adult (AYA) patients with cancer have not seen the same improvements in survival over the years as their pediatric and older adult counterparts. Some evidence has suggested that this may in part be a result of low AYA participation in clinical trials, limiting advances in...
Association of Incomplete Polyp Removal With Risk of Postcolonoscopy Colorectal Cancer
A multicenter cohort study found that incomplete polyp removal—polyp removal where neoplastic tissue is found in any of the marginal biopsies—is a likely contributor to neoplasia recurrence and interval colorectal cancer. The results highlight the critical importance of polyp resection technique in ...
Conquer Cancer Announces 2021 Israel Cancer Research Fund Career Development Award
Conquer Cancer, the ASCO Foundation, is pleased to announce Shlomit Strulov Shachar, MD, of Tel Aviv Sourasky Medical Center, is the recipient of the 2021 Conquer Cancer–Israel Cancer Research Fund (ICRF) Career Development Award. Dr. Shachar’s proposed study, entitled “Identifying Molecular...
ASCO and Community Oncology Alliance Publish Standards for Oncology Medical Home Model
ASCO and the Community Oncology Alliance (COA) have published standards for the oncology medical home (OMH), a comprehensive system of care delivery that supports coordinated, efficient, accessible, and evidence-based care.1 The standards serve as a roadmap for practice...
